NeuroPace has secured $67m to accelerate the commercialization of its RNS implantable brain stimulator for the treatment of medication-refractory focal epilepsy. The funding will also help the company expand RNS’ indication to include children.
The funding round is led by Accelmed Partners with participation from an unnamed strategic investor, Revelation Partners, Soleus Capital, and returning investors KCK Group and Orbimed Advisors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?